Dr. Lal Pathlabs Limited — Call Transcript 2020

Oct 29, 2020

==> picture [24 x 41] intentionally omitted <==

==> picture [253 x 31] intentionally omitted <==

October 29, 2020

National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Sandra Kurla Complex Sandra (E) Mumbai - 400 051.

Bombay Stock Exchange Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001

Dear Sir/Madam,

Sub: Intimation of Conference Call for Investors/Analysts for Q2 & H1 FY 21

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Friday, November 6, 2020 at 3:30 P.M. 1ST to discuss the financial and operating performance for 02 & H1 FY 21.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

==> picture [71 x 73] intentionally omitted <==

For Dr. Lal PathLabs Limited Rajat Ka ra Company Secretary and Legal Head

Encl: As above

Regd. Office: Dr. Lal f'dL'1Labs Ltd. Bi,cd< E, Se::-' r- I 8, I' : ,in/, New Deft- i - I ; :;:2s. +9 I -I 1-Y::s·· :JO. Fax: +91-1 1-:z;; : ; .z 134 Corpc'rate Office: Dr. Lal f,,U1Lab! L7". I:?� Fl:, - .� To�;er 8. �AS Tcv.t'� 11,:,-..;;. ity. Se-:tnr-38. Gurui:vam - 122 00 I. Haryanc +91-124-3( i6-5C•O. F,n: +91-124-4234-�.'..B E-m;,if: ,�1r�:nlat =·•·.-,:1-i,�ns cnrn, Web: wwwl;,/p;>t1.:•bS.M'11. CIN No.: L74t. CLl'i'i5PLGi6:o:�9

Conference Call Invitation

==> picture [209 x 72] intentionally omitted <==

Dr. Lal PathLabs’ Q2 & H1 FY21 Concall Invitation

Q2 & H1 FY21 Earnings Conference Call Friday, November 06, 2020 at 03:30pm IST

Gurugram, October 29, 2020:

Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q2 & H1 FY21 results. DLPL will be represented by (Hony) Brig. Dr. Arvind Lal – Executive Chairman, Dr. Om Prakash Manchanda – Managing Director, Mr. Bharath U – Chief Executive Officer and Mr. Ved Prakash Goel – Chief Financial Officer. We would also have Mr. Rajat Kalra - Company Secretary & Head of Investor Relations.

The conference call will be initiated with a brief discussion by the management on the Q2 & H1 FY21 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	 03:30pm IST on Friday, November 06, 2020
Pre-registration	 To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.  You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode &pin to connect to call.
Universal Access	 +91 22 6280 1141  +91 22 7115 8042
Local Access	 +91-7045671221 (Available all over India)
	 USA – 18667462133
Conference dial-in	 UK – 08081011573
International Toll Number	 Singapore – 8001012045
	 Hong Kong – 800964448
Replay	 +91 22 71945757 / +91 22 66635757  05023 (passcode)  Valid from Nov 6, 2020 to Nov 13, 2020

-ENDS-

Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-I8, Rohini, New Delhi – 110085, Tel: +91-11 30258600. Fax: +91-11-2788-2134 Corporate Office: Dr. Lal PathLabs Ltd., 12[th] Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122001, Haryana, Tel: +91-124-3016-500, Fax: +91-124-4234-468 E-mail: lalpathlabs@lalpathlabs.com, Web: www.lalpathlabs.com, CIN: L74899DL 1995PLC065388

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.

As on March 31, 2020, DLPL’s has 216 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). In FY19 & FY20, DLPL collected and processed approximately 41.8 million samples and 47.7 million samples from approximately 17.6 million and 19.4 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388 Website: https://www.lalpathlabs.com/

For further information please contact:

Ved Goel / Rajat Kalra Siddharth Rangnekar / Nishid Solanki Dr. Lal PathLabs Limited CDR India E-mail: ved.goel@lalpathlabs.com Email: siddharth@cdr-india.com rajat.kalra@lalpathlabs.com nishid@cdr-india.com

Disclaimer: Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Regd. Office: Dr. Lal PathLabs Ltd., Block E, Sector-I8, Rohini, New Delhi – 110085, Tel: +91-11 30258600. Fax: +91-11-2788-2134 Corporate Office: Dr. Lal PathLabs Ltd., 12[th] Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram - 122001, Haryana, Tel: +91-124-3016-500, Fax: +91-124-4234-468 E-mail: lalpathlabs@lalpathlabs.com, Web: www.lalpathlabs.com, CIN: L74899DL 1995PLC065388